How to Get Belsomra (Suvorexant) in District of Columbia

What Is Suvorexant and Why Is It Prescribed?

Suvorexant is the first FDA-approved dual orexin receptor antagonist, blocking the wake-promoting neuropeptides orexin-A and orexin-B to allow sleep onset without suppressing GABAergic pathways the way benzodiazepines and Z-drugs do. The FDA approved Belsomra in August 2014 for adults with insomnia characterized by difficulty falling asleep, staying asleep, or both.

In the key phase 3 trial by Herring et al. (Lancet Neurology, 2014; N=3,291), suvorexant at doses of 40 mg and 20 mg significantly improved subjective total sleep time (sTST) and reduced subjective time to sleep onset (sTSO) versus placebo over 3 months. The 20 mg dose increased sTST by a mean of 22 minutes compared with placebo at month 1. Polysomnography data showed suvorexant reduced wake after sleep onset (WASO) by roughly 25 minutes at month 1 in the 40/30 mg group [1].

The drug carries Schedule IV classification from the DEA, reflecting a lower abuse potential than benzodiazepines (also Schedule IV) based on clinical data showing minimal euphoria at therapeutic doses [2]. Standard dosing begins at 10 mg nightly, with a maximum of 20 mg, taken within 30 minutes of bedtime and only when the patient can stay in bed for at least 7 hours.

Telehealth Prescribing for Belsomra in DC

DC fully authorizes telehealth prescribing of Belsomra. A DC-licensed clinician can evaluate, diagnose, and prescribe suvorexant during a synchronous video or audio visit without requiring an in-person encounter first. This applies to MDs, DOs, nurse practitioners, and physician assistants alike.

DC is one of the jurisdictions where nurse practitioners hold full practice authority, meaning NPs can independently evaluate insomnia and prescribe Schedule IV controlled substances such as suvorexant without a collaborating physician agreement. PAs in DC prescribe under a collaborative agreement with a licensed physician but can also issue Belsomra prescriptions [3].

Because suvorexant is Schedule IV, the prescriber must hold an active DEA registration and comply with DC Board of Pharmacy rules for controlled substance electronic prescribing (EPCS). Since January 2025, DC aligns with the federal mandate requiring EPCS for all controlled substance prescriptions sent to retail pharmacies [4]. Telehealth platforms operating in DC typically handle EPCS compliance on the backend, so patients experience no additional friction.

A typical telehealth workflow in DC takes 3 to 5 business days from initial consultation to pharmacy pickup:

1. Schedule a video visit with a DC-licensed prescriber.
2. Discuss sleep history, prior medication trials, and contraindications (narcolepsy, concurrent CYP3A4 inhibitors, pregnancy).
3. Receive the e-prescription routed to your DC pharmacy.
4. Pick up or request delivery of the dispensed medication.

DC Medicaid Coverage and Prior Authorization

DC Medicaid (administered through the Department of Health Care Finance) covers Belsomra with prior authorization (PA). The PA requirement reflects suvorexant's brand-only pricing, which averages $400 to $450 for a 30-day supply at retail without insurance [5].

What Prior Authorization Typically Requires

PA documentation for Belsomra under DC Medicaid generally includes:

• Diagnosis confirmation. Clinical documentation of insomnia disorder (ICD-10: G47.00 or G47.09) lasting 3 months or longer.
• Step therapy evidence. Documentation that the patient has tried and failed, or has a contraindication to, at least one first-line generic agent. DC Medicaid formularies commonly require a trial of generic zolpidem, zaleplon, or low-dose doxepin before approving a DORA.
• Clinical rationale. A brief statement explaining why suvorexant is medically necessary for this patient. History of paradoxical reactions to Z-drugs, fall risk with benzodiazepines, or substance use disorder history are common supporting reasons.
• Prescriber attestation. The requesting prescriber must be enrolled as a DC Medicaid provider or be part of a group practice with active enrollment.

PA turnaround in DC averages 24 to 72 hours for standard requests. Urgent requests may be processed within 24 hours. Denials can be appealed through the DC Fair Hearing process, and the prescriber can request a peer-to-peer review with the managed care organization's pharmacy director [6].

Commercial Insurance

Most commercial plans in DC cover Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) with copays ranging from $40 to $75 per fill. Some plans also require PA or step therapy. Merck offers a manufacturer savings card that can reduce copays to as low as $0 for commercially insured patients, though this benefit does not apply to government-funded insurance including Medicaid, Medicare Part D, or TRICARE [5].

Pharmacy Access and 503A Compounding in DC

DC retail pharmacies including CVS, Walgreens, and independent pharmacies stock or can order Belsomra within 1 to 2 business days. The drug is distributed through standard pharmaceutical wholesalers (McKesson, AmerisourceBergen, Cardinal Health).

503A compounding pharmacies in DC are licensed by the DC Board of Pharmacy and can compound suvorexant formulations for individual patients with a valid prescription. A 503A pharmacy may compound suvorexant into alternative dosage forms (for instance, a liquid suspension for patients with dysphagia) when a prescriber documents a medical need that the commercial tablet does not meet [7].

Key distinctions for DC residents:

• 503A pharmacies compound patient-specific preparations based on individual prescriptions. They operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and are inspected by the DC Board of Pharmacy.
• 503B outsourcing facilities produce larger batches without patient-specific prescriptions. While 503B facilities registered with the FDA can ship into DC, they are not a common source for suvorexant specifically, since the commercial product is widely available.

Mail-order pharmacy is another option. DC residents can use mail-order pharmacies licensed in DC to receive Belsomra shipped directly to their address. For controlled substances, the receiving address must match the patient's address on file, and the pharmacy must comply with DC's chain-of-custody requirements for Schedule IV shipments [4].

Labs and Clinical Screening Before Starting Belsomra

No routine laboratory testing is required before initiating suvorexant. The American Academy of Sleep Medicine (AASM) clinical practice guideline for pharmacologic treatment of chronic insomnia (2017) does not mandate bloodwork prior to prescribing DORAs [8].

A prescriber may order specific tests based on clinical judgment:

• Thyroid panel (TSH). If the patient presents with fatigue, weight changes, or other symptoms suggesting thyroid dysfunction as a contributor to sleep disturbance.
• Hepatic function (ALT, AST). Suvorexant is extensively metabolized by CYP3A4 in the liver. The FDA label recommends caution in patients with hepatic impairment, though no dose adjustment is needed for mild-to-moderate impairment. Severe hepatic impairment has not been studied [2].
• Polysomnography. If the clinician suspects obstructive sleep apnea, periodic limb movement disorder, or narcolepsy. Suvorexant is contraindicated in narcolepsy because blocking orexin signaling in a patient already deficient in orexin could worsen cataplexy and excessive daytime sleepiness.
• Depression screening (PHQ-9). Insomnia frequently coexists with depression. The AASM guideline recommends assessing for psychiatric comorbidities before prescribing any hypnotic [8].

In practice, most telehealth and in-person prescribers in DC will conduct a structured sleep history (sleep onset latency, total sleep time, wake episodes, Epworth Sleepiness Scale or Insomnia Severity Index) and review the medication list for CYP3A4 interactions before writing the prescription.

Drug Interactions and Safety Considerations

Suvorexant is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors reduce suvorexant clearance and increase exposure, requiring dose adjustments or avoidance.

| Interaction Category | Examples | Clinical Action | |---|---|---| | Strong CYP3A4 inhibitors | Ketoconazole, itraconazole, clarithromycin, ritonavir | Contraindicated with suvorexant per FDA label [2] | | Moderate CYP3A4 inhibitors | Diltiazem, erythromycin, fluconazole, verapamil | Reduce suvorexant dose to 5 mg; monitor for excess sedation | | Strong CYP3A4 inducers | Rifampin, carbamazepine, phenytoin | May reduce suvorexant efficacy substantially | | CNS depressants | Alcohol, benzodiazepines, opioids | Additive sedation; avoid concurrent use when possible |

The FDA label also warns about complex sleep behaviors (sleepwalking, sleep-driving, preparing food while asleep) reported with suvorexant, though the incidence in clinical trials was low (fewer than 1% of participants) [2]. Patients should be counseled to discontinue the drug and contact their prescriber if any complex sleep behavior occurs.

A 2020 meta-analysis published in the Journal of Clinical Sleep Medicine found that DORAs as a class had lower rates of next-day residual sedation compared with Z-drugs, with suvorexant 20 mg showing no significant difference from placebo on next-morning driving performance in patients who took the drug 9 hours before testing [9].

Suvorexant vs. Other Insomnia Medications Available in DC

DC prescribers have access to the full range of FDA-approved insomnia treatments. Here is where suvorexant fits:

• Zolpidem (Ambien). Generic, low cost ($5 to $15 per month). Works via GABA-A receptor modulation. Higher rates of complex sleep behaviors and next-day impairment, especially in women. The FDA cut the recommended dose for women to 5 mg in 2013 [10].
• Lemborexant (Dayvigo). A newer DORA approved in 2019. The SUNRISE-2 trial (N=949) showed lemborexant 5 mg and 10 mg improved sTSO and sTST versus placebo at 6 months, with a safety profile similar to suvorexant [11].
• Low-dose doxepin (Silenor). A tricyclic antidepressant at 3 mg or 6 mg for sleep maintenance insomnia. No controlled substance classification. Less effective for sleep onset.
• Eszopiclone (Lunesta). Generic Z-drug with sleep onset and maintenance indications. Common side effect: unpleasant metallic taste (up to 34% of patients at the 3 mg dose).

Suvorexant's clinical niche is the patient who needs both sleep onset and sleep maintenance benefit, prefers a non-GABA mechanism, or has a history of tolerance or dependence concerns with Z-drugs. The Herring et al. trial showed no evidence of rebound insomnia or withdrawal symptoms after 3 months of nightly use followed by abrupt discontinuation [1].

Transferring a Belsomra Prescription to DC

Patients relocating to DC or visiting from another state can transfer an existing Belsomra prescription to a DC pharmacy. For Schedule IV drugs, the transfer process follows DEA regulations:

• The prescription must have remaining refills.
• The receiving DC pharmacy contacts the originating pharmacy to initiate the transfer.
• Only one transfer is permitted for Schedule III-V prescriptions under federal law, though some states allow additional transfers within the same pharmacy chain [4].
• If no refills remain, the patient needs a new prescription from a DC-licensed prescriber. A telehealth visit with a DC-licensed provider is the fastest route.

Patients with out-of-state Medicaid will need to apply for DC Medicaid separately. DC Medicaid does not accept out-of-state prior authorizations, so a new PA will be required [6].

Timeline: From First Visit to First Dose

For most DC patients, the process takes 3 to 7 business days:

• Day 1. Telehealth or in-person consultation. The prescriber evaluates insomnia history, screens for contraindications, and sends the e-prescription.
• Days 1 to 2. Pharmacy receives and processes the prescription. If the drug is in stock, it is ready for pickup the same or next day.
• Days 2 to 5 (if PA required). The pharmacy or prescriber's office submits PA to the insurer. Standard PA decisions take 24 to 72 hours. Urgent appeals are processed within 24 hours.
• Day 3 to 7. Patient picks up or receives Belsomra.

If a 503A compounding pharmacy is preparing a custom formulation, add 2 to 5 business days for compounding and quality checks.